Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

May 26, 2005 10:36 ET

REMINDER/Bioxel Pharma Inc.: Annual General Meeting of Shareholders

MONTREAL, QUEBEC--(CCNMatthews - May 26 2005) - Management of Bioxel Pharma Inc.(TSX VENTURE:BIP) cordially invites you to attend the Corporation's Annual General Meeting of Shareholders which will be held on:



Thursday, May 26, 2005 at 1:30 p.m.
Montreal Bonaventure Hilton Hotel
Le Portage Room
900 de la Gauchetiere Street West
Montreal


In 2004, Bioxel Pharma significantly increased its capacity to manufacture cGMP paclitaxel, an ingredient widely used in chemotherapy treatments worldwide. A few months ago, the Corporation also appointed a new President and CEO in addition to revising its growth strategy so as to achieve ambitious goals: double its revenues in each of the next three years, generate positive cash flows in 2006 and be profitable by 2007. At the Annual Meeting, Pascal Delmas, President and CEO, and Andre Boulet, Chairman of the Board, will notably outline the strategy Bioxel plans to implement in order to achieve its business and financial objectives. The Corporation's results for the first quarter of the current fiscal year will also be disclosed.

A press briefing for members of the media will be held right after the meeting.

For those unable to attend the event, the proceedings will be broadcast (audio mode and PowerPoint) at 1:30 p.m. Thursday, May 26, 2005, on http://www.bioxelpharma.com and will subsequently be available on this website.

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

Bioxel Pharma's common shares trade on the TSX Venture Exchange under the ticker symbol BIP.

Contact Information

  • CG3 Inc.
    Daniel Rheault
    (514) 286-5600
    or
    CG3 Inc.
    Suzanne Roy
    (514) 286-5600